- Home
- EVCM vs GLPG Comparison
EVCM vs GLPG Comparison
Compare EVCM & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVCM
- GLPG
- Stock Information
- Founded
- EVCM 2006
- GLPG 1999
- Country
- EVCM United States
- GLPG Belgium
- Employees
- EVCM N/A
- GLPG N/A
- Industry
- EVCM EDP Services
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- EVCM Technology
- GLPG Health Care
- Exchange
- EVCM Nasdaq
- GLPG Nasdaq
- Market Cap
- EVCM 2.1B
- GLPG 2.1B
- IPO Year
- EVCM 2021
- GLPG 2005
- Fundamental
- Price
- EVCM $8.46
- GLPG $31.33
- Analyst Decision
- EVCM Hold
- GLPG Hold
- Analyst Count
- EVCM 9
- GLPG 4
- Target Price
- EVCM $11.89
- GLPG $31.33
- AVG Volume (30 Days)
- EVCM 240.7K
- GLPG 218.5K
- Earning Date
- EVCM 11-06-2025
- GLPG 11-05-2025
- Dividend Yield
- EVCM N/A
- GLPG N/A
- EPS Growth
- EVCM N/A
- GLPG N/A
- EPS
- EVCM N/A
- GLPG N/A
- Revenue
- EVCM $718,038,000.00
- GLPG $336,643,201.00
- Revenue This Year
- EVCM N/A
- GLPG $1.77
- Revenue Next Year
- EVCM $6.07
- GLPG $0.44
- P/E Ratio
- EVCM N/A
- GLPG N/A
- Revenue Growth
- EVCM 22.13
- GLPG 10.31
- 52 Week Low
- EVCM $7.66
- GLPG $22.36
- 52 Week High
- EVCM $12.34
- GLPG $37.78
- Technical
- Relative Strength Index (RSI)
- EVCM 26.06
- GLPG 44.85
- Support Level
- EVCM $8.40
- GLPG $31.05
- Resistance Level
- EVCM $9.01
- GLPG $33.12
- Average True Range (ATR)
- EVCM 0.56
- GLPG 0.77
- MACD
- EVCM -0.34
- GLPG 0.10
- Stochastic Oscillator
- EVCM 17.47
- GLPG 45.65
About EVCM EverCommerce Inc.
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. With a platform serving approximately 708,000 customers across three core verticals, including numerous micro-verticals, their solutions address diverse needs within these sectors. Revenue is mostly generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty. The majority of customers contribute modest revenue, with a small percentage contributing higher amounts.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.